(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
本日の出来高 | 235 000 |
平均出来高 | 159 271 |
時価総額 | 722.68M |
EPS | HKD-0.0352 ( Q4 | 2023-12-31 ) |
Last Dividend | HKD0.00420 ( 2022-06-07 ) |
Next Dividend | HKD0 ( N/A ) |
P/E |
-19.40 (Sector) 0 (Industry) 0 |
ATR14 | HKD0.0300 (3.09%) |
Fusen Pharmaceutical 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Fusen Pharmaceutical 財務諸表
Annual | 2023 |
収益: | HKD565.61M |
総利益: | HKD299.51M (52.95 %) |
EPS: | HKD-0.0500 |
FY | 2023 |
収益: | HKD565.61M |
総利益: | HKD299.51M (52.95 %) |
EPS: | HKD-0.0500 |
FY | 2022 |
収益: | HKD491.76M |
総利益: | HKD225.02M (45.76 %) |
EPS: | HKD-0.0458 |
FY | 2021 |
収益: | HKD385.66M |
総利益: | HKD211.13M (54.75 %) |
EPS: | HKD0.0210 |
Financial Reports:
No articles found.
Fusen Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.00620 | 2018-09-13 |
Last Dividend | HKD0.00420 | 2022-06-07 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.0436 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.08 | -- |
Div. Sustainability Score | 1.527 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
07 Jun 2022 | HKD0.00420 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
17 Sep 2021 | HKD0.00680 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
08 Jun 2021 | HKD0.00540 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
15 Sep 2020 | HKD0.00510 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
03 Jul 2020 | HKD0.00400 | 31 Mar 2020 | 06 Jul 2020 | 10 Aug 2020 |
13 Sep 2019 | HKD0.00330 | 30 Aug 2019 | 16 Sep 2019 | 29 Nov 2019 |
03 Jul 2019 | HKD0.00860 | 29 Mar 2019 | 04 Jul 2019 | 09 Aug 2019 |
13 Sep 2018 | HKD0.00620 | 31 Aug 2018 | 14 Sep 2018 | 30 Nov 2018 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3600.HK | Ex Dividend Knight | 2023-09-12 | Annually | 0 | 0.00% | |
0882.HK | Ex Dividend Knight | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
2005.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0450.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
1586.HK | Ex Dividend Knight | 2023-10-06 | Annually | 0 | 0.00% | |
0083.HK | Ex Dividend Knight | 2023-10-27 | Semi-Annually | 0 | 0.00% | |
6626.HK | Ex Dividend Knight | 2023-09-04 | Annually | 0 | 0.00% | |
1100.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
2338.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
0683.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0641 | 1.500 | -1.283 | -1.924 | [0 - 0.5] |
returnOnAssetsTTM | -0.0270 | 1.200 | -0.900 | -1.080 | [0 - 0.3] |
returnOnEquityTTM | -0.0612 | 1.500 | -1.791 | -2.69 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.853 | 0.800 | -0.735 | -0.588 | [1 - 3] |
quickRatioTTM | 0.329 | 0.800 | -2.77 | -2.22 | [0.8 - 2.5] |
cashRatioTTM | 0.0524 | 1.500 | -0.820 | -1.230 | [0.2 - 2] |
debtRatioTTM | 0.256 | -1.500 | 5.73 | -8.60 | [0 - 0.6] |
interestCoverageTTM | 6.34 | 1.000 | 8.76 | 8.76 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0979 | 2.00 | -0.0326 | -0.0653 | [0 - 30] |
freeCashFlowPerShareTTM | -0.186 | 2.00 | -0.0931 | -0.186 | [0 - 20] |
debtEquityRatioTTM | 0.611 | -1.500 | 7.56 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.530 | 1.000 | 4.51 | 4.51 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0379 | 1.000 | -1.241 | -1.241 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.213 | 1.000 | -2.30 | -2.30 | [0.2 - 2] |
assetTurnoverTTM | 0.421 | 0.800 | -0.527 | -0.422 | [0.5 - 2] |
Total Score | 1.527 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -18.64 | 1.000 | -1.984 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0612 | 2.50 | -1.151 | -2.69 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.186 | 2.00 | -0.0621 | -0.186 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0979 | 2.00 | -0.0326 | -0.0653 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.943 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.130 | 1.000 | -5.74 | 0 | [0.1 - 0.5] |
Total Score | -2.08 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Fusen Pharmaceutical
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。